This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Acetazolamide Acetazolamide sodium

May 20, 2025

Therapeutic category

Diuretics

Non-proprietary name

Acetazolamide

Acetazolamide sodium

Safety measure

PRECAUTIONS should be revised.

Current	Revision
8. IMPORTANT PRECAUTIONS	8. IMPORTANT PRECAUTIONS
(N/A)	Acute myopia, angle closure glaucoma, and/or choroidal effusion
	may occur. Patients should be instructed to consult an
	ophthalmologist immediately if they experience abnormalities such
	as a rapid reduction in visual acuity and eye pain.
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1 Clinically Significant Adverse Reactions	11.1 Clinically Significant Adverse Reactions
(N/A)	Acute myopia, angle closure glaucoma, choroidal effusion
	It has been reported that reduced visual acuity, aggravation of angle
	closure glaucoma, and choroidal effusion occurred in overseas
	cases of patients treated with this drug for drug-induced glaucoma.
	Also, there have been reports that acute myopia (including blurred
	vision and reduced visual acuity), angle closure glaucoma, and
	choroidal effusion occurred in overseas cases of patients
	administered this drug for treatments including the adjustment of
	intraocular pressure before and after cataract surgery.
	When abnormalities such as a rapid reduction in visual acuity and
	eye pain are observed, the possibility that they are caused by this
	drug should be considered. If a causal relationship to this drug is
	suspected, appropriate measures such as discontinuation of this
	drug should be taken.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

(References) Pathak-Ray, V., et al.: Am. J. Ther. 2020; 27(6): e680-e682 Malagola, R., et al.: Drug Des. Devel. Ther. 2013; 7: 33-36